Biotechnology company focused on developing innovative therapies and solutions for genetic diseases.
GRI Bio, Inc., headquartered in La Jolla, California, operates as a clinical-stage biopharmaceutical firm specializing in the treatment of inflammatory, fibrotic, and autoimmune diseases across the United States. Founded in 2009 and previously known as Glycoregimmune, Inc., the company focuses on advancing therapeutic solutions aimed at addressing significant medical challenges. Its diverse product pipeline includes GRI-0621, currently in phase II clinical development for idiopathic pulmonary fibrosis, alongside GRI-0803, undergoing phase I trials for systematic lupus erythematosus. Additionally, GRI-0124 is in pre-clinical stages targeting primary sclerosing cholangitis, with GRI-0729 also advancing in pre-clinical development.
Innovation remains at the forefront of GRI Bio's strategy, which extends to the development of ADAIR and ADMIR therapies for attention-deficit/hyperactivity disorder (ADHD). These initiatives underscore the company's commitment to addressing a broad spectrum of medical needs through cutting-edge research and development. Located in the biopharmaceutical hub of La Jolla, GRI Bio leverages its strategic position to collaborate with leading research institutions and drive advancements in therapeutic discovery.
With a dedicated focus on improving patient outcomes and advancing treatment options, GRI Bio continues to expand its capabilities and pipeline. The company's robust research efforts and clinical advancements exemplify its mission to deliver transformative therapies that enhance the quality of life for patients affected by complex diseases globally.